This article is available online at http://www.jlr.org screening programs ( 4, 5 ) have, however, drastically improved long-term survival and a great number of patients have remained asymptomatic with proper preventive measures during the fi rst years of life ( 4 ). However, as there is no prevalent VLCAD mutation and VLCAD mutations cannot be correlated to residual VLCAD activity, as measured in fi broblasts or lymphocytes, the late-onset disease phenotype varies greatly ( 6 ). Neonatal screening programs are thus identifying more and more patients carrying VLCAD mutations whose clinical outcome cannot be predicted at the time of diagnosis. Therefore, the effect of possible disease triggers, such as exercise-stress, and their resulting metabolic phenotype (i.e., acylcarnitine and/or acyl-CoA accumulation) need to be identifi ed.
pooled. The pooled supernatants were centrifuged at 1000 g for 5 min to remove any remaining cellular debris. For analysis, sample volumes were reduced by approximately 50% using evaporation at 40°C under air.
For LC-tandem MS analysis, a Waters 2795 Alliance HPLC system (Waters, Milford, UK) equipped with a thermostated autosampler was used for solvent delivery and sample introduction. Assay samples were placed in a cooled sample tray, and 20 l were injected onto a reversed-phase Symmetry C18 column (3.5 ; 7.5 × 4.6 mm; WAT066224; Waters), protected by a guard column (SecurityGuard C18 ODS; 4 × 2.0 mm; Phenomenex). C18:2-CoA, C18:1-CoA, C16:0-CoA, and C17:0-CoA were eluted isocratically with 55% (v/v) acetonitrile in 10 mM NH 4 Ac (pH = 6.5) at a fl ow rate of 0.6 ml/min. The eluate was delivered into a Quattro Micro API tandem mass spectrometer (Micromass, Cambridge, UK) with an ESI probe in positive-ion mode. The waste valve was used to discard early-eluting salts from contaminating the mass spectrometer. The injection interval was 5 min. Nitrogen was used as drying gas at a fl ow rate of 700 L/h. The collision energy using argon as collision gas was 35 eV. The declustering potential was 45 V, and the ion source temperature was 120°C. Compounds were detected in the multiple-reaction monitoring (MRM) mode. A representative chromatogram, with (A) and without (B) internal standard C17:0-CoA, is shown in Fig. 1 . Specifi c transitions were used for each metabolite, but HPLC separation remained necessary to remove interfering compounds, such as salts, present in muscle extracts, thereby preventing tandem MS apparatus contamination.
Acylcarnitine and carnitine analysis
In tissues, analysis of carnitine and acylcarnitines was performed according to van Vlies et al. ( 17 ) . Briefl y, 50 mg of blotted skeletal muscle was lyophilized for 12 h, including internal standards (16.25 16 -acylcarnitine). The lyophilized tissues were pulverized and dissolved in 1 ml of 80% v/v acetonitrile. After homogenization and centrifugation, the supernatant was dried. Finally, carnitine and acylcarnitines were analyzed by electrospray ionization tandem mass spectrometry as their butyl esters and resuspended in 100 µL ACN/H 2 O (50/50% v/v).
Citrate synthase activity
Citrate synthase enzyme activity of tissue homogenates was determined to characterize Krebs cycle activity as described previously ( 18 ) . Samples were assayed in duplicate in fl at-bottom microtiter plates, the absorption coeffi cient was adjusted to the reaction volume (i.e., calculated light path). The media used in the assays were adjusted to 0.1% Triton X-100 to obtain maximal enzyme activities in tissue homogenates.
Cytochrome c oxidase subunit 3 mRNA expression
Expression of mitochondrial DNA encoded cytochrome c oxidase subunit 3 (cox3) mRNA expression was performed as described previously ( 19 ) to determine the relative mitochondrial quantity. ␤ -Actin mRNA expression was unaffected by our experimental design and was used as a reference. Cox4 mRNA/cDNA concentration was normalized for the concentrations of ␤ -actine mRNA/cDNA in the same sample. Values are stated as percentage of the sedentary control samples.
Protein determination
Protein concentration of tissue homogenates was determined by the BCA assay (Pierce). The BCA reagent was supplemented with 0.1% (v/v) Triton X-100. BSA was used as standard.
Taken together, although the accumulation of longchain acylcarnitines in VLCADD-patients and in the corresponding mouse model has been demonstrated, an increase in long-chain acyl-CoA levels has, so far, only been assumed.
For the fi rst time, we are now able to simultaneously measure acyl-CoA and acylcarnitines in muscle from VLCAD-defi cient mice after exercise stress. Both measurements are performed by tandem mass spectrometry in the same muscle sample, and therefore, allow accurate and direct correlation of both metabolites in sedentary and exercised muscle.
MATERIALS AND METHODS

Reagents
Heptadecanoyl-CoA (C17-CoA) was purchased from Sigma (Deisenhofen, Germany) as Li + salts and stored at -20°C. Internal standard heptadecanoyl-CoA was prepared by dissolving in methanol to obtain a concentration of 2.5 mM and stored at Ϫ 80°C until use.
Animals
VLCAD-defi cient mice were generated as described in detail previously ( 7 ) . Experiments were performed on second-to thirdgeneration intercrosses of C57BL6+129sv VLCAD genotypes. Littermates served as controls, and genotyping of mice was performed as described previously ( 16 ) . Mice were fed with a standard chow diet (MZ Extrudat from sniff® containing 4.5% w/w crude fat, corresponding to 13% of total metabolizable energy according to the Atwater System) and received tap water ad libitum. As mice are nocturnal animals, treadmill running was performed during the dark cycle. All animal studies were in accordance with the Heinrich-Heine-University Medical Center and Institutional Animal Care and Use Committee guidelines. 
Training protocol
Acyl-CoA analysis
Hind leg skeletal muscle (100-200 mg) was taken up in fi ve volumes of extraction buffer (1:1:1 iso-propanol / acetonitrile / 10 mM NH 4 Ac, pH = 5.0) and minced on ice with scissors. Five nmoles of heptadecanoyl-CoA (C17:0-CoA) were added as internal standard, and the tissue was homogenized using an UltraTurrax ® . Next, the homogenate was centrifuged at 1000 g for 5 min, the supernatant was collected, and the pellet was rehomogenized in fi ve volumes of extraction buffer. The homogenate was centrifuged at 1000 g for 5 min, and the supernatants were 3.29, 6.22 ± 2.78, and 11.29 ± 3.27 nmol · g Ϫ 1 wet weight, respectively (n = 5); in exercised VLCAD Ϫ / Ϫ : 17.91 ± 4.62, 14.58 ± 3.08, and 26.50 ± 9.16 nmol · g Ϫ 1 wet weight, respectively; P < 0.05 (n = 4)] ( Fig. 2B ) . Wild-type mice showed a signifi cant increase in C16:0-carnitine after 2 h of belt running, compared with sedentary palmitoyl-carnitine muscle content [6.64 ± 1.14 and 11.46 ± 1.08 nmol · g Ϫ 1 wet weight for sedentary versus exercised WT mice; P < 0.05 (n = 4)] ( Fig. 2B ) . We observed no signifi cant differences between groups in muscle medium-chain octanoyl (C8:0)-carnitine content (data not shown).
Muscle free L-carnitine content
Exercise resulted in lowering of carnitine in both WT and VLCAD Ϫ / Ϫ muscle. This reduction was signifi cant in 
DISCUSSION
In the present study, long-chain acylcarnitines and acylCoAs were measured to monitor the effect of exercise stress on VLCAD-defi cient muscle. We were able to show for the fi rst time that exercise stress, consisting of treadmill running, resulted in a signifi cant, corresponding increase in C16:0, C18:1, and C18:2-carnitine and -CoA in VLCAD Ϫ / Ϫ mouse muscle. Accumulation of long-chain acylcarnitines is well documented and has been implicated in the development of rhabdomyolysis in VLCAD-defi cient patients ( 20 ) . However, it is unknown whether, and to what extent, this increase in long-chain acylcarnitines is mirrored by an increase in acyl-CoA esters of corresponding chain length. The mouse model of VLCAD-defi ciency also displays acylcarnitine accumulation in tissues during fasting and exercise stress ( 16 ) and is, therefore, a suitable animal model to study the effects of VLCAD-defi ciency at a cellular level. First, we measured if mitochondrial content was altered in exercised VLCAD Ϫ / Ϫ muscle. This is of importance because in heart muscle approximately 95% of the cellular CoA pool is located inside mitochondria ( 21 ) . Previous studies have shown that mitochondrial density increases in oxidative soleus and heart muscle of VLCAD-defi cient
Data analysis and statistics
Data were acquired and analyzed using MassLynx NT v4.0 software (Micromass, UK). Data were analyzed with Origin 6.0 (Microcal Software Inc., Northhampton, MA). If not stated otherwise, reported data are presented as arithmetic means ± standard deviation (SD) with n denoting the number of animals. Statistical analyses were performed using Student's t -test. Differences between means were considered signifi cant if P < 0.05.
RESULTS
Animal condition and mitochondrial content
In contrast to WT mice, VLCAD Ϫ / Ϫ mice had diffi culty maintaining a running speed of 15 m/min for the full 120 min, resulting in shorter running times for VLCAD Ϫ / Ϫ mice ( Table 1 ). To stress the mice to their maximal capacity, different running times were needed. Body weights were similar for sedentary WT and VLCAD Ϫ / Ϫ mice ( Table 1 ) .
Possible proliferation of muscle mitochondria, due to VLCAD-defi ciency and/or exercise, was studied by measuring indirect marker enzyme citrate synthase and the expression of cytochrome c oxidase subunit 3 (cox3) mRNA. Muscle citrate synthase activity (in mU · mg protein
) and cox3 expression were not signifi cantly different in WT as well as VLCAD Ϫ / Ϫ mouse skeletal muscle ( Table 1 ) .
Muscle acyl-CoA and acylcarnitine content
We fi rst measured muscle acylcarnitine and acyl-CoA content in WT and VLCAD Ϫ / Ϫ mice under sedentary con- Expressed as citrate synthase activity (mU · mg protein1) and Cox3 mRNA expression (as % of wild-type). VLCAD, very long-chain acyl-CoA dehydrogenase. in WT mouse muscle was comparable to reported values in literature, obtained with both HPLC and mass spectrometry techniques (24) (25) (26) (27) (28) . Exercise stress signifi cantly increased long-chain acyl metabolites, with C18:1 chain-length having the most pronounced effect. Elevation of C18:1-carnitine and C18:1-CoA was approximately 4-fold and 3-fold, respectively, in exercised VLCAD Ϫ / Ϫ muscle, as compared with sedentary WT muscle. Unlike WT-exercised muscle, all long-chain acyl CoA esters signifi cantly increased in VLCAD Ϫ / Ϫ muscle upon exercise ( Fig. 2 ) , illustrating the impact of workload on the VLCAD-defi cient phenotype and the extent of activated fatty acid oxidation. In addition, it appears that during periods of elevated workload, the carnitine pool of VLCAD-defi cient muscle can no longer adequately scavenge acyl moieties, resulting in a signifi cant increase in muscle long-chain acyl-CoA esters. Importantly, this mice ( 7 ). In glycolytic skeletal gastrocnemius and extensor digitorum longus muscle from WT and VLCAD Ϫ / Ϫ mice, we compared mitochondrial content, based on citrate synthase enzyme activity, as indirect marker, and Cox3 mRNA expression, and observed that, in contrast to oxidative muscle, mitochondrial content was identical for WT and VLCAD Ϫ / Ϫ muscle at rest and did not increase due to exercise ( Table 1 ) . The observation of similar citrate synthase activity in sedentary and exercised murine skeletal muscle is in line with previous work from Jeneson et al. ( 22 ) , where treadmill running had no effect on glycolytic fast-twitch extensor digitorum longus citrate synthase content. Taken together, these data suggest that in oxidative muscle mitochondrial proliferation occurs as compensatory mechanism, on the energy supply side of cellular energy homeostasis, in an effort to counteract impaired fatty acid oxidation. In contrast, in glycolytic skeletal muscles, this cellular remodelling appears not to take place. Long-chain acylcarnitine content, by measuring C16:0, C18:1, and C18:2-carnitine, was slightly higher in VLCAD Ϫ / Ϫ striated skeletal muscle under sedentary conditions, as published previously ( 16 ) . However, this increase collagen deposition, and vacuolated myocytes, which may be indicative of cytotoxicity ( 7 ). These cellular alterations in VLCAD-defi cient heart were accompanied by changes in mitochondrial ultrastructure, an adaptive response also observed in VLCAD Ϫ / Ϫ solues muscle cells ( 7 ) . However, it is currently still unknown whether these changes are the direct consequence of accumulating (long-chain) acylcarnitines and acyl-CoA esters. Of note, calculation of absolute cytosolic concentrations based on tissue content (in nmol · g
should be treated with caution because free long-chain fatty acid and acyl-CoA concentrations are buffered by fatty acid and acyl-CoA binding proteins inside the cell ( 30 ) , thereby lowering the concentration on free acyl compounds.
In conclusion, we demonstrate for the fi rst time that long-chain acylcarnitines and acyl-CoA esters increase and directly correlate in VLCAD Ϫ / Ϫ mouse muscle after exercise. However, the question whether exercise-induced accumulation of acyl esters is an important factor in disease pathogenesis cannot be answered at this time.
exercise-induced fast increase in long-chain acyl-CoA esters is absent in WT muscle. The effect of enhanced workload on long-chain acylCoA ester levels can be better illustrated by plotting the exercise-induced increase in acyl-CoA and acylcarnitine as percentage of sedentary levels ( Fig. 3 ) . We clearly observe that exercise results in a stronger accumulation of acylcarnitines than acyl-CoAs in both WT as well as VLCAD Ϫ / Ϫ mice. And although the magnitude by which both longchain acylcarnitines and acyl-CoAs increase is higher in VLCAD Ϫ / Ϫ as compared with WT muscle ( Fig. 3 ) , importantly in relation to each other, these acyl CoA esters appear to be well equilibrated by the action of carnitine acyltransferases. This is observed in WT and VLCAD Ϫ / Ϫ muscle, as the exercise-induced increase in long-chain acylcarnitines is approx. 2.5-fold higher than the increase in corresponding acyl-CoA esters ( Fig. 3 ) . Furthermore, the proposed role of the carnitine pool functioning as acyl scavenger is supported by our measurements of muscle free carnitine, demonstrating a signifi cant drop in free carnitine in VLCAD Ϫ / Ϫ muscle upon exercise. Thus, during periods of elevated workload, the acylation state of the cytosolic carnitine pool increases more than that of the mitochondrial pool, indicative of acyl compounds being exported out of the muscle cell ( 29 ) . This observation fi ts well with the increased levels of long-chain acylcarnitines in serum and blood from VLCAD Ϫ / Ϫ mice ( 16, 23 ) , as acylcarnitines in blood would accumulate over time due to cellular effl ux. Acylcarnitines are known to have unspecifi c cytotoxic effects ( 12 ) and long-chain acyl-CoAs are known to inhibit the mitochondrial adenine nucleotide translocator ( 15 ) , however, further studies have to determine which of these two metabolites is more cytotoxic in vivo. Thus, in addition to impaired energy production from long-chain fatty acids due to the enzyme defect itself, toxic effects of accumulating acylcarnitines and acyl-CoA esters may play an important role in disease pathogenesis. Interestingly, detailed histological investigation of VLCAD Ϫ / Ϫ mouse heart has indeed demonstrated an increase in degenerative fi bers, 
